Actively Recruiting
Alleviating Persistent Dyspnea in Amyotrophic Lateral Sclerosis Patients Treated With Non-Invasive Ventilation Through Immersive Virtual Reality
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-02-25
35
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The evolution of amyotrophic lateral sclerosis (ALS) is marked by dyspnea, anxiety and pain, major determinants of suffering induced by this disease. The only palliative treatment for respiratory failure is non-invasive ventilation (NIV), which compensates failing respiratory muscles and relieves dyspnea, improves quality of life and increases life expectancy. In ALS patients, the persistence of dyspnea outside of NIV sessions has highlighted the need for therapeutic alternatives in the treatment of persistent dyspnea, including immersive virtual reality (IVR) and auditory distraction through music (music therapy). This study evaluates the effect of IVR on respiratory discomfort in ALS patients with persistent dyspnea treated with NIV.
CONDITIONS
Official Title
Alleviating Persistent Dyspnea in Amyotrophic Lateral Sclerosis Patients Treated With Non-Invasive Ventilation Through Immersive Virtual Reality
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years old or older
- Diagnosis of ALS confirmed by El Escorial revised criteria
- Respiratory failure from diaphragmatic dysfunction treated with non-invasive ventilation for over one month
- Care provided in an outpatient day care hospital setting
- Persistent breathlessness at rest with a score of 3 or higher on a 0 to 10 scale while semi-sitting
- Clinically stable with no acute cardiac, respiratory, or neurological failure requiring hospitalization in the past 4 weeks
- Provided free, prior, and informed written consent to participate
- Covered by French social security health insurance
You will not qualify if you...
- Neurological disorders diagnosed within the past year, including dementia or brain diseases like tumors, stroke, or Parkinson's
- Diagnosed psychiatric illness such as severe depression or psychosis, or currently receiving antipsychotic treatment
- Fear of heights (acrophobia)
- Claustrophobia
- Sensitivity to light (photophobia)
- Hearing loss
- Visual impairment
- Under legal guardianship or curatorship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Service de Pneumologie
Paris, France, France, 75013
Actively Recruiting
Research Team
C
Capucine MORELOT-PANZINI
CONTACT
T
Thomas SIMILOWSKI
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here